Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of SPR741 in Healthy Volunteers
NCT03022175Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gram-negative bacterial infections comparing SPR741 with Placebo (2 arms). Primary endpoints: Adverse Events, Clinical Laboratory Testing and 4 more. Started Dec 2016; status: completed.
02
Drugs
SPR741
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT03022175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022175.